AIGH Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

AIGH Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,674,812	Closed	-$6.79M	–	60
2023 Q1	$6.79M	Sell	2,674,812 -1,482,079	-36%	-$2.93M	2.5%	14
2022 Q4	$7.77M	Buy	4,156,891 +269,719	+7%	+$672K	2.56%	15
2022 Q3	$9.99M	Buy	3,887,172 +500,000	+15%	+$1.24M	3.1%	11
2022 Q2	$6.54M	Buy	3,387,172 +247,458	+8%	+$540K	1.72%	15
2022 Q1	$9.32M	Buy	3,139,714 +800,607	+34%	+$3.01M	2.29%	14
2021 Q4	$10.5M	Buy	2,339,107 +729,709	+45%	+$3.46M	3.2%	11
2021 Q3	$7.82M	Buy	1,609,398 +686,619	+74%	+$3.78M	1.64%	18
2021 Q2	$6.29M	Buy	922,779 +173,171	+23%	+$1.4M	1.13%	24
2021 Q1	$5.29M	Hold	749,608	–	–	1.11%	27
2020 Q4	$4.69M	Buy	+749,608	New	+$4.41M	1.91%	16

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

AIGH Capital Management's PRTK Position: Q2 2023 in Review

AIGH Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 2,674,812 shares — an estimated $6.79M sold.

AIGH Capital Management first reported a position in PRTK in Q4 2020 and held it in 10 quarters. The position peaked at $10.5M in Q4 2021. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

AIGH Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
AIGH Capital Management sold 2,674,812 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $6.79M.
AIGH Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 10 quarters.
AIGH Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $10.5M in Q4 2021.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on AIGH Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.